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E
m
M
B
a
b
9
a
A
R
R
A
A
K
C
Z
M

F
1
t
h
h
C
r
o
i
d
s
e
m
e
A
h
2Toxicology Reports 2 (2015) 858–863
Contents lists available at ScienceDirect
Toxicology  Reports
j our na l ho me  page: www.elsev ier .com/ locate / toxrep
valuation  of  zinc  effect  on  cadmium  action  in  lipid  peroxidation  and
etallothionein  levels  in  the  brain
arcos  M.  Bragaa,b,∗,  Tuiskon  Dicka, Diogo  L.  de  Oliveiraa, Adriele  Scopel-Guerraa,
en  Hur  M.  Mussulinia,  Diogo  O.  Souzaa, João  Batista  T.  da  Rochab
Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, CEP 90035-003 Porto Alegre, RS, Brazil
Departamento de Bioquímica e Biologia Molecular, Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria, Santa Maria, RS
7105-900, Brazil
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 26 March 2015
eceived in revised form 29 May  2015
ccepted 31 May  2015
vailable online 5 June 2015
eywords:
admium
inc
etallothionein
a  b  s  t  r  a  c  t
Cadmium  (Cd)  is a known  hepato-  and nephrotoxic  pollutant  and  zinc  (Zn)  metalloproteins  are important
targets  of Cd.  Hence,  the administration  of Zn  may  mitigate  Cd  toxic  effects.  However,  the  interaction
of  Cd  and  Zn  has  been  little  investigated  in  the  brain. Previously,  we  reported  a protective  effect  of Zn
on  mortality  caused  by Cd  in  rats. Here,  we tested  whether  the  protective  effect  of  Zn  could  be related
to  changes  in  brain  Zn-proteins,  metallothionein  (MT)  and  -aminolevulinate  dehydratse  (-ALA-D).
Male  adult  rats  were  daily  administered  for 10 days  with  Zn  (2  mg  kg−1), Cd (0.25  and  1  mg  kg−1)  and
0.25  mg  kg−1 of  Cd  plus  Zn  and 1 mg kg−1 of  Cd  plus  Zn. The  body  weight  loss,  food  intake  deprivation,
and  mortality  occurred  in  1 mg  kg−1 of Cd, but Zn  co-administration  did  mitigate  these  effects.  The  brain
Zn  content  was  not  modiﬁed  by  treatment  with  Cd,  whereas  cerebral  Cd levels  increased  in animals
−1-Aminolevulinate dehydratase
ood intake
exposed  to Cd.  The  administration  of 0.25  mg kg of Cd (with  or without  Zn)  induced  lipid peroxidation
and decreased  MT  concentration,  but 2  mg  kg−1 of Zn  and  1 mg  kg−1 of  Cd  did  not  change  these  parameters.
Brain  -ALA-D  was  not  modiﬁed  by Cd  and/or  Zn  treatments.  Since  the  co-administration  of  Zn  did  not
attenuate  the  changes  induced  by Cd  in  the brain,  our  results  suggest  that  the protective  effect  of  Zn  on
impairments  caused  by Cd  in animal  status  is weakly  related  to a cerebral  interaction  of  these  metals.
© 2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the  CC  BY. Introduction
The metal cadmium (Cd) is a widespread environmental con-
aminant [1] and a potential toxin that may  harmfully affect human
ealth. Cadmium has a long biological half-life [2] and testicular,
epatic and renal cells are particularly sensitive to exposure to
d [3–6]. Accordingly, Cd intoxication has been associated with
eactive species over production, mitochondrial injury, lipid per-
xidation and cellular death in liver [7,8] and kidney [9].
Cadmium can have also neurotoxic effects. In several exper-
mental models, it has been reported that Cd induces oxidative
amage in brain mitochondria [10,11], impairs synaptic transmis-
ion [12,13], and reduces neuronal differentiation and axonogen-
sis [14]. Thus, occupational exposure to Cd have been linked to
otor and memory deﬁciencies [15].
∗ Corresponding author at: Departamento de Bioquímica, ICBS Universidade Fed-
ral  do Rio Grande do Sul, Rua Ramiro Barcelos 2600-Anexo, CEP: 90035-003 Porto
legre, RS, Brazil. Tel.: +55 51 33085555.
E-mail address: marcosmbraga@gmail.com (M.M.  Braga).
ttp://dx.doi.org/10.1016/j.toxrep.2015.05.014
214-7500/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access license  (http://creativecommons.org/licenses/by/4.0/).
The molecular toxicity of Cd is mainly related to direct action
in zinc (Zn)-dependent biological pathways [16]. Cadmium expo-
sure is able to alter Zn transporters expression in zebraﬁsh [17]
and cause Zn accumulation in different tissues of rodents [16,18]. In
addition, the Zn-dependent activity of the -aminolevulinate dehy-
dratase (-ALA-D) is a potential target of Cd, which can replace Zn of
the active site of the mammalian enzyme [19–21]. The expression of
metallothionein (MT), an important protein in Zn homeostasis, has
been also induced after Cd administration [22]. Overall, Cd effects
may  be mitigated by Zn, including Cd-induced oxidative stress [23].
The antagonist effect of Zn on Cd toxicity has led to proposition
that Cd is an antimetabolite of Zn [16]. However, the interaction
between Cd and Zn after systemic exposure has been little explored
in the brain.
Zinc has important role in the brain and could be a highly sen-
sitive target to action of Cd. There are a considerable number of
proteins that bind to Zn in the central nervous system (CNS), for
instance, -ALA-D [24] and MTs  [25]. Moreover, a brain fraction
of Zn, named chelatable Zn pool, is found free or loosely bound
to biomolecules, and it is localized abundantly in synaptic vesicles
[26]. This indicates that Zn participates in the regulation of synaptic
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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hysiology. As corollary, we can suppose that the interaction
etween Cd and Zn could be more critical in the brain.
The aim of this work was to investigate whether the protective
ffect of Zn on systemic effects of Cd could be related to changes in
rain Zn-proteins, similar with those observed in peripheral tissues
f adult rats [27–29]. Thus, the animal status (e.g., body weight gain
nd food intake) was evaluated during the exposure to the metals.
peciﬁcally, we measured the content of Zn and Cd in the brain of
ats after in vivo exposure to metals. Furthermore, we evaluated the
ipid peroxidation rate, the levels of MT,  and the -ALA-D activity.
. Materials and methods
.1. Chemicals
-aminolevulinic acid (-ALA), DL-dithiothreitol (DTT), rabbit
etallothionein-I, o-phenylendiamine, thiobarbituric acid (TBA)
nd malonaldehyde bis- (dimethyl acetal) were obtained from
igma (St. Louis, MO,  USA); mouse anti-metallothionein-I/II, and
eroxidase-conjugated to goat anti-mouse IgG were purchased
rom Dako Corporation (Carpinteria, CA, USA).
.2. Animals
Male Wistar rats (±80 days and ±240 g) were obtained from
ur animal facility. Animals were maintained under a controlled
nvironment (three rats housed per cage, room temperature 22 ◦C,
tandard light/dark cycle of 12 h, and water and food provided ad
ibitum). Animal care was  followed in accordance with the “National
nstitutes of Health Guide for Care and Use of Laboratory Animals”,
nd all experiments were approved by Ethics Committee of Uni-
ersidade Federal do Rio Grande do Sul.
.3. Treatments and tissue preparation
The rats (n = 9 animals per group) were daily exposed to Cd
nd/or Zn during 10 days. The metals were injected via intraperi-
oneal (i.p.), as a model for parenteral exposure of Cd, i.e.,  inhalation
30]. Based on previous studies [16,31,32], animals were adminis-
ered with neurotoxic doses of Cd in the presence or absence of
upplementary dose of Zn. Experimental groups consisted in (i)
aCl 0.9% (control group), (ii) 2 mg  kg−1 of Zn, (iii) 0.25 mg  kg−1 of
d, (iv) 0.25 mg  kg−1 of Cd plus 2 mg  kg−1 of Zn, (v) 1 mg  kg−1 of Cd;
vi) 1 mg  kg−1 of Cd plus 2 mg  kg−1 of Zn. The metals were injected
s acetate salts. Twenty-four hours after the last injection, the rats
ere anesthetized with sodium thiopental (40 mg/kg, 1 ml/kg, i.p.)
nd euthanized by decapitation. The whole brain was removed and
eparated in order to evaluate Zn and Cd levels and biochemical
arameters. Importantly, the same brains were used to perform all
ests. For biochemical analysis the brains were separately placed
n ice and homogenized in saline (1:5) and centrifuged at 4000 g
t 4 ◦C for 10 min. The remaining supernatant was used to deter-
ine the activity of the -ALA-D, MT  content, and thiobarbituric
cid-reactive substances (TBARS).
.4. Body weight and food intake
The body weight gain of each animal was evaluated during expo-
ure to the metals and the data were expressed as cumulative body
eight gain per animal (n = 9 animals per group). The food intake
er cage was also determined in each day of exposure to the metals,
nd the results were divided by number of animals in the cage. The
ood intake data were expressed as cumulative food intake (g) per
nimal (n = 3 independent experiments per group).eports 2 (2015) 858–863 859
2.5. Zn and Cd determination
The content of Zn and Cd was determined by atomic absorption
spectrometry following the US EPA 3052 protocol [33]. All analyses
were carried out at the Centro de Ecologia of Universidade Federal
do Rio Grande do Sul. The samples were digested in closed vials with
9 ml  of 65% nitric acid and 3 ml  of 30% hydrogen peroxide in boiling
water. Zinc content in the samples (control, n = 6; 2 mg  kg−1 of Zn,
n = 5; 0.25 mg  kg−1 of Cd, n = 6; 0.25 mg  kg−1 of Cd plus 2 mg  kg−1
of Zn, n = 6; 1 mg  kg−1 of Cd, n = 6; 1 mg kg−1 of Cd plus 2 mg kg−1
of Zn, n = 6) was determined by a Perkin-Elmer 3300 ﬂame atomic
absorption spectrometer and Cd levels (control, n = 5; 2 mg kg−1 of
Zn, n = 3; 0.25 mg  kg−1 of Cd, n = 6; 0.25 mg  kg−1 of Cd plus 2 mg kg−1
of Zn, n = 5; 1 mg  kg−1 of Cd, n = 5; 1 mg  kg−1 of Cd plus 2 mg kg−1 of
Zn, n = 4) were estimated with a Perkin-Elmer SIMAA-6000 graphite
furnace atomic absorption spectrometer. The minimum detection
was 0.495 and 0.008 g/g for Zn and Cd, respectively. All analyzes
were determined with ultrapure reagents to avoid sample contam-
ination.
2.6. Thiobarbituric acid-reactive substances
The lipid peroxidation was  measured in the samples (control,
n = 6; 2 mg  kg−1 of Zn, n = 5; 0.25 mg  kg−1 of Cd, n = 6; 0.25 mg  kg−1
of Cd plus 2 mg  kg−1 of Zn, n = 8; 1 mg  kg−1 of Cd, n = 6; 1 mg kg−1
of Cd plus 2 mg  kg−1 of Zn, n = 6) by relatively non-speciﬁc TBARS
method according to Draper and Hadley [34]. Brieﬂy, 80 l of
homogenized samples (2 g/l  protein) were precipitated with
160 l of TCA (15%) and centrifuged at 4000 g for 10 min. The super-
natants (60 l) and standard malondialdehyde (MDA) solutions
were transferred to 96 well microplate and each well was  ﬁlled
with deionized water in order to obtain the equal volume. Next,
100 l of TBA (0.67%) was  added in each well and the microplate
was sealed for heating in boiling water bath at 90 ◦C for 30 min.
The TBARS levels were determined at 532 m and the values were
expressed as mol  MDA  equivalents/mg protein.
2.7. Metallothionein content
Metallothionein-I and -II (MT) were measured by enzyme-
linked immunoassay (control, n = 7; 2 mg kg−1 of Zn, n = 7;
0.25 mg  kg−1 of Cd, n = 9; 0.25 mg  kg−1 of Cd plus 2 mg  kg−1 of Zn,
n = 8; 1 mg  kg−1 of Cd, n = 7; 1 mg  kg−1 of Cd plus 2 mg  kg−1 of Zn,
n = 7) [35]. The MT-III was not analyzed, because this isoform is
not sensitive to Cd [36]. The experiment was  conducted in 96-
well microtiter plates at room temperature, and MT-I was  used
as standard. The plates were incubated with samples and stan-
dard concentrations of MT  for 1 h. Then, the plates were washed
three times with phosphate buffered saline plus 0.05% Tween 20
(washing solution). A blocking solution (washing solution plus 1%
bovine serum albumin) was  applied for 30 min, and the plates
were washed three times. Then, mouse anti-metallothionein-I/II
was incubated for 30 min  and washed three times. Afterwards,
peroxidase-conjugated to goat anti-mouse was  incubated for
30 min  and washed three times. Finally, o-phenylendiamine was
incubated in the dark for 30 min  for colorimetric reaction. The reac-
tion was stopped with 3 M HCl and the plate was read at 490 m.
The values were expressed as g MT/mg  protein.
2.8. ı-ALA-D activity
The enzyme activity (control, n = 5; 2 mg kg−1 of Zn, n = 7;
0.25 mg  kg−1 of Cd, n = 7; 0.25 mg  kg−1 of Cd plus 2 mg  kg−1 of Zn,
n = 5; 1 mg  kg−1 of Cd, n = 7; 1 mg  kg−1 of Cd plus 2 mg  kg−1 of Zn,
n = 7) was evaluated as previously described [37]. The formation
rate of porphobilinogen (PBG) was  obtained in medium containing
8 logy Reports 2 (2015) 858–863
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Fig. 1. Animal status. The cumulative body weight gain (A) and the cumulative
food intake (B) are represented during exposure to the metals. The lines indicate
the results for control (black), 2 mg kg−1 of Zn (red), 0.25 mg  kg−1 of Cd (green),
0.25  mg  kg−1 of Cd plus 2 mg kg−1 of Zn (faint green), 1 mg  kg−1 of Cd (blue),
and  1 mg kg−1 of Cd plus 2 mg kg−1 of Zn (faint blue). Values are expressed as
mean ± S.E.M. Data were analyzed by two-way repeated-measures ANOVA followed
by  Duncan’s multiple range post hoc test. Different letters indicate statistical differ-
ences at p < 0.05. (For interpretation of the references to color in this ﬁgure legend,
the  reader is referred to the web version of this article.)
Table 1
Zinc and cadmium concentrations in nervous tissue.
Groups Zn* Cd#
Control 14.02 ± 0.31 NDa
2 mg kg−1Zn 13.72 ± 0.22 NDa
0.25 mg  kg−1Cd 14.18 ± 0.63 122.27 ± 22.16b
0.25 mg  kg−1Cd + 2 mg kg−1Zn 13.22 ± 0.46 89.02 ± 21.01b
1 mg.kg-1Cd 13.07 ± 0.32 209.86 ± 20.86c
1 mg kg−1Cd + 2 mg kg−1Zn 13.29 ± 0.38 198.81 ± 17.72c60 M.M. Braga et al. / Toxico
 mM -ALA, 80 mM sodium phosphate buffer (pH 6.4) and brain
upernatant (100 g of protein per assay). To obtain -ALA-D reac-
ivation (n = 5–7), DTT (2 mM)  was also added to the medium in
dditional set of tubes as reported by Perottoni et al. [38]. The reac-
ion was performed at 37 ◦C for 2 h, and PBG was determined using
hrlich’s reagent at 555 m,  with a molar absorption coefﬁcient of
.1 × 104 M−1 for the Ehrlich-PBG salt.
.9. Protein concentration
The protein content was estimated according to Lowry et al. [39].
.10. Statistical analysis
Statistical results were obtained by STATISTICA/w 5.0 software
nd reported as mean ± S.E.M. The body weight gain and food intake
ere analyzed by two-way repeated-measures ANOVA, using days,
d and Zn as factors. The neurochemical data were evaluated by
wo-way ANOVA, using Cd and Zn as factors. Post hoc comparisons
ere performed using Duncan’s multiple range test, and p < 0.05
as considered statistically signiﬁcant.
. Results
.1. Body weight and food intake
Statistical analysis by two-way repeated-measures ANOVA
ndicated a signiﬁcant effect of Cd (F[2,46] = 22.7; p < 0.001),
ays (F[9,414] = 10.4; p < 0.001), Zn × Cd interaction (F[2,46] = 9.8;
 < 0.001), Cd × days interaction (F[18,414] = 16.3; p < 0.001), and
n × Cd × days interaction (F[18,414] = 10.5; p < 0.001) on body
eight gain (Fig. 1A). Based on the initial and ﬁnal weight difference
f each animal, the control group showed a signiﬁcant mean weight
ain (25.4 ± 2.6 g) during the trial period, while Zn (0.4 ± 3.2 g),
.25 mg  kg−1 of Cd (0.8 ± 3.8 g) and 0.25 mg  kg−1 of Cd plus Zn
1.1 ± 1.9 g) did not show signiﬁcant increase in body weight after
reatment period. The administration of 1 mg  kg−1 of Cd caused
 signiﬁcant decrease in the body weight of rats (−34.6 ± 3.8 g).
owever, co-administration of Zn attenuated the Cd-induced body
eight loss (−10.8 ± 4.2 g).
The analysis across 1-day intervals (Fig. 1B) by two-way
epeated-measures ANOVA indicated a signiﬁcant effect of
d (F[2,12] = 27.5; p < 0.001), days (F[9,108] = 1178.2; p < 0.001),
n × Cd interaction (F[2,12] = 9.3; p < 0.01), Cd × days interac-
ion (F[18,108] = 38.7; p < 0.001), and Zn × Cd × days interaction
F[18,108] = 15.4; p < 0.001) on food intake. After 10 days of treat-
ent, Zn (155.9 ± 4.5 g), 0.25 mg  kg−1 of Cd (149.0 ± 8.0 g) and
.25 mg  kg−1 of Cd plus Zn (150.9 ± 9.2 g) did show a slight decrease
n the food intake compared to the control group (214.0 ± 4.6 g).
n contrast, the exposure to 1 mg  kg−1 of Cd caused a signiﬁcant
ecrease in the food intake of animals (73.4 ± 15.4 g), and the co-
dministration of Zn did attenuate this Cd effect (125.8 ± 13.5 g).
n addition, co-administration of Zn also abolished the mortality
aused by 1 mg  kg−1 of Cd (∼22%).
.2. Zn and Cd content
Two-way ANOVA showed only a signiﬁcant effect of Cd in the
ccumulation of cerebral Cd (F[2,22] = 52.16; p < 0.001). The treat-
ents did not modify the levels of Zn in the brain of rats (Table 1).
admium was not detected in the brains of the control and the
n-treated group. However, Cd administration increased the lev-
ls of Cd in the brain and the accumulation was dose-dependent.
ccordingly, treatment with 1 mg  kg−1 of Cd did induce higher
ccumulation of Cd in the brain compared to 0.25 mg  kg−1 of Cd.
Different letters indicate statistical difference with p < 0.05. ND – not detectable.
* Data are presented as g/g tissue, means ± S.E.M., n = 5–6.
# Data are presented as g/g tissue, means ± S.E.M., n = 3–6.
M.M. Braga et al. / Toxicology Reports 2 (2015) 858–863 861
Fig. 2. Brain concentration of TBARS after administrations with metals (n = 5–8). The
gray and black bars indicate treatments with and without 2 mg  kg−1 of Zn, respec-
tively. The x-axis represents administrations with 0, 0.25, and 1 mg  kg−1 of Cd. Values
are expressed as mean ± S.E.M. Data were analyzed by two-way ANOVA followed by
Duncan’s multiple range post hoc test. Different letters indicate statistical differences
at p < 0.05.
Fig. 3. Brain concentration of MT  after treatments with metals (n = 7–9). The gray
and black bars indicate treatments with and without 2 mg  kg−1 of Zn, respectively.
The x-axis represents administrations with 0, 0.25, and 1 mg kg−1 of Cd. Values are
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Table 2
Speciﬁc activity and reactivation index of -ALA-D in nervous tissue.
Groups Speciﬁc activitya Reactivationb
Control 24.0 ± 3.4 10.3 ± 1.5
2  mg kg−1Zn 24.3 ± 2.0 11.4 ± 2.9
0.25 mg kg−1Cd 19.9 ± 1.8 12.8 ± 1.3
0.25 mg kg−1Cd + 2 mg kg−1 Zn 23.2 ± 1.5 10.4 ± 0.8
1  mg kg−1Cd 22.3 ± 1.8 13.8 ± 2.4
1  mg kg−1Cd + 2 mg kg−1Zn 23.9 ± 1.3 11.3 ± 1.6
a Data are presented as mol PBG/min/mg protein, means ± S.E.M., n = 5–7.xpressed as mean ± S.E.M. Data were analyzed by two-way ANOVA followed by
uncan’s multiple range post hoc test. Different letters indicate statistical differences
t p < 0.05.
admium accumulation was not modiﬁed by co-administration of
n (Table 1).
.3. TBARS levels
The two-way ANOVA test showed only a signiﬁcant effect of Cd
n the TBARS levels (F[2,31] = 7.53; p < 0.01) (Fig. 2). The adminis-
ration of Zn, 1 mg  kg−1 of Cd and 1 mg  kg−1 of Cd plus Zn caused
o effect on TBARS. In contrast, the animals showed a signiﬁcant
ncrease in TBARS content after treatment with 0.25 mg  kg−1 of Cd
r 0.25 mg  kg−1 of Cd plus Zn.
.4. MT  levels
The statistical analysis indicated only a signiﬁcant effect of Cd
n MT  levels (F[2,39] = 21.98; p < 0.001). The MT  levels are depicted
n Fig. 3. The groups administered with 0.25 mg  kg−1 of Cd and
.25 mg  kg−1 of Cd plus Zn showed signiﬁcant reduction in amount
f MT  in the brain, while 1 mg  kg−1 of Cd (with or without Zn) did
ot change the content of MT.  Moreover, Zn treatment did not mod-
fy MT  content, and Zn co-administration did not interfere also in
d effects in MT  levels.b Data are presented as percentage of basal -ALA-D activity augment,
means ± S.E.M., n = 5–7.
3.5. ı-ALA-D activity
The two-way ANOVA analysis for activity and reactivation of
-ALA-D also yielded no signiﬁcant effect. The cerebral -ALA-
D activities were not modiﬁed in treatments with Zn and/or Cd
(Table 2). Similarly, the evaluation of enzyme reactivation indicated
no change in this parameter (Table 2).
4. Discussion
The interaction between Cd and Zn has been studied in the
last decade [16]. The interest in Cd–Zn interaction is due to Cd be
an environmental pollutant with potential action in Zn-dependent
pathways in biological systems. The exposure to Cd can modify Zn
homeostasis by inducing the transport of Zn to target organs such
as liver and kidneys [16]. However, Zn can blunt or reverse the
toxicity of Cd [16]. In previous study, we have also reported that
Zn protected against mortality and loss of body weight caused by
Cd, and these results were associated to a mitigating effect of Zn
against Cd-induced changes in MT  levels in the liver of rats [27].
In the present work, we  have investigated whether the interaction
between these metals could also be extended to the brain. Here,
we observed that the mortality, body weight loss, and food intake
deprivation caused by subacute administration of Cd was  associ-
ated to cerebral accumulation of Cd, but Zn levels were not altered
in the nervous tissue of Cd-treated rats. The Zn-dependent activity
of brain -ALA-D was not also modiﬁed after treatments with Cd
and/or Zn. However, the treatment with 0.25 mg kg−1 of Cd caused
a decrease in MT  levels and a stimulation in the lipid peroxidation
in the brain. Finally, the co-administration of Zn did not attenuate
any effect induced by Cd in the brain.
It is well known that Zn is an essential metal in the body, where
presents cofactor function on important enzymes [40]. In addition,
Zn has special role in the brain of vertebrates, because it is also a
neuromodulator in excitatory synapses [26]. In contrast to Zn, Cd
is a toxic metal that scarcely reaches the brain under normal con-
ditions due to the presence of the blood brain barrier (BBB) [41].
However, our results clearly demonstrate that i.p. administration
of Cd resulted in accumulation of this metal in the brain. Thus, this
change could indicate a possible alteration in cerebral Zn content,
since it has been reported a modiﬁcation in tissue levels of Zn in
Cd target organs [16]. Nevertheless, we observed no modiﬁcation
in cerebral Zn caused by Cd accumulation, such as demonstrated
in previous studies [28–30]. Moreover, our data also showed that
Zn co-administration was unable to alter Zn and Cd levels in the
brain. These results could indicate that brain responds differently to
exposure to Cd in comparison to other tissues. However, a previous
study has reported that Zn pre-treatment promoted simultane-
ously a lower and higher accumulation of Cd in the brain and liver,
respectively [42]. Thus, it is possible that cerebral accumulation of
Cd was  not enough to trigger an increase in Zn content as observed
previously in the liver.
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The co-administration of Zn did cause no effect in the cerebral
ccumulation of Cd, but the protective action of Zn on harmful
ffects caused by Cd in animals status could be explained for a neu-
ochemical action of these metals. In the current study, we  have
valuated TBARS and MT  content, because Cd has known action on
oth biochemical endpoints [7,22]. Although, we  obtained a con-
iderable background in TBARS technique by non-speciﬁc reactions
43–46], which could have underestimated lipid peroxidation, our
esults showed that exposure to lowest dose of Cd did increase lipid
amages as previously reported [47]. Interestingly, we  observed
hat these effects were related to reduction in MT  levels. Since MT
resents Cd chelating properties as well as scavenging ability of
eactive oxygen species [48–51], it is supposed that lipid damage
erformed by 0.25 mg  kg−1 of Cd did occur as consequence of low
evels of MT.  This hypothesis is further supported by administra-
ion of 1 mg  kg−1 of Cd, which did not change lipid peroxidation
ate and MT  levels. Consequently, it could be expected a protec-
ive mechanism of Zn involving overexpression of MT.  However,
t was noted that co-administration of Zn was not able to modify
he effects of Cd on lipid peroxidation and MT  levels in the brain.
here are scarce data about the evaluation of these parameters in
he brain after Cd and Zn exposure, but it has been reported that
he methamphetamine-induced lipid peroxidation was attenuated
y an increment on MT  levels in dopaminergic cells after Zn pre-
reatment [52,53]. Moreover, in vivo studies showed an increase in
ranscriptional expression of MT  caused by intracerebroventricu-
ar injection of Zn [54,55]. In fact, these studies indicate the similar
bility of Zn as inducer of MT  expression in the brain, such as
bserved in other tissues [22]. As we observed no changes on total
n content in the brain, the administration of 2 mg  kg−1 of Zn by
.p. route, as we  performed, was possibly insufﬁcient to modulate
T content and lipid peroxidation in the nervous tissue. Therefore,
t is suggested that the protective mechanism of Zn on effects of Cd
n animal status is not related to lipid peroxidation and MT  levels
n the brain.
An important role of the MT  is the control of cellular lev-
ls of Zn [48,50]. Indeed, the change in MT  levels caused by Cd
ould affect the function of Zn-dependent biomolecules. In order
o obtain data about this hypothesis, we evaluated the thiol- and
n-dependent acitivity of -ALA-D [21,37]. Based on our results,
he cerebral enzyme function was preserved in any of the exper-
mental groups, including those animals with low levels of MT.
ther works have reported also no change in brain -ALA-D activ-
ty of rodents after exposure to Cd [24,56,57]. Since the -ALA-D is
ne of the enzymes most sensitive to cellular levels of Zn and Cd
58,59], all these results support that the Zn-dependent activities
ere probably little affected in the brain after Zn and Cd treat-
ents.
In the present study, the animal status showed an attenuating
ffect of Zn on Cd toxicity, but Zn administration did not modify
ny action performed by Cd in neurochemical parameters. Interest-
ngly, these data indicate a protective Zn mechanism weakly related
o the brain. However, this does not exclude fully the involvement
f the brain on mitigatory function of Zn on Cd. Indeed, other poten-
ial molecules as well as speciﬁc cerebral structures may  be a target
f Zn–Cd interaction in the brain. For instance, calcium (Ca) uptake
60] and the expression of Ca transporter-1 [61] are deeply modu-
ated by Cd and Zn in the kidney tissue and these same Ca molecular
omponents could be sensitive to interactive effect of Zn and Cd in
he brain. In addition, some structural brain parts could be differ-
ntly affected for both metals, since a small fraction of total Zn
rain, the chelatable Zn pool, is heterogeneously distributed in the
NS [26]. In this case, the structures with high and/or low levels of
helatable Zn could present an interactive effect of Cd and Zn, which
e did not observe in the whole brain. Thus, future additional stud-
es, investigating Zn–Cd interaction in Ca-related molecules and
[eports 2 (2015) 858–863
chelatable Zn of brain structures, can complement our ﬁndings on
total Zn content in the whole brain.
In summary, this is the ﬁrst study considering multiple expo-
sures of Cd and Zn on these Zn-dependent pathways. Under a whole
brain approach, we  demonstrated that the brain is also subject to Cd
action, leading to lipid damage associated to reduction in the levels
of MT.  However, in contrast to liver, Zn treatment did not modify the
cerebral effects caused by Cd. Therefore, these data strongly indi-
cate that the protective effect of Zn on impairments induced by Cd
in animal status is predominantly restricted to molecular mecha-
nisms at peripheral tissues, because these organs are possibly most
susceptible to Cd accumulation than the brain.
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